Literature DB >> 24092852

Pathogenesis and current approaches to control of varicella-zoster virus infections.

Anne A Gershon1, Michael D Gershon.   

Abstract

Varicella-zoster virus (VZV) was once thought to be a fairly innocuous pathogen. That view is no longer tenable. The morbidity and mortality due to the primary and secondary diseases that VZV causes, varicella and herpes zoster (HZ), are significant. Fortunately, modern advances, including an available vaccine to prevent varicella, a therapeutic vaccine to diminish the incidence and ameliorate sequelae of HZ, effective antiviral drugs, a better understanding of VZV pathogenesis, and advances in diagnostic virology have made it possible to control VZV in the United States. Occult forms of VZV-induced disease have been recognized, including zoster sine herpete and enteric zoster, which have expanded the field. Future progress should include development of more effective vaccines to prevent HZ and a more complete understanding of the consequences of VZV latency in the enteric nervous system.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24092852      PMCID: PMC3811230          DOI: 10.1128/CMR.00052-13

Source DB:  PubMed          Journal:  Clin Microbiol Rev        ISSN: 0893-8512            Impact factor:   26.132


  178 in total

1.  Envelopment of varicella-zoster virus: targeting of viral glycoproteins to the trans-Golgi network.

Authors:  Z Zhu; M D Gershon; Y Hao; R T Ambron; C A Gabel; A A Gershon
Journal:  J Virol       Date:  1995-12       Impact factor: 5.103

2.  Association of an attack of varicella and an achalasia.

Authors:  F Castex; F Guillemot; N Talbodec; J F Colombel; J C Paris; A Cortot
Journal:  Am J Gastroenterol       Date:  1995-07       Impact factor: 10.864

3.  Experience and reason: twenty-year follow-up of protective immunity of the Oka strain live varicella vaccine.

Authors:  Y Asano; S Suga; T Yoshikawa; I Kobayashi; T Yazaki; M Shibata; K Tsuzuki; S Ito
Journal:  Pediatrics       Date:  1994-10       Impact factor: 7.124

4.  Virologic characteristics of subclinical and symptomatic genital herpes infections.

Authors:  A Wald; J Zeh; S Selke; R L Ashley; L Corey
Journal:  N Engl J Med       Date:  1995-09-21       Impact factor: 91.245

5.  The incidence of herpes zoster.

Authors:  J G Donahue; P W Choo; J E Manson; R Platt
Journal:  Arch Intern Med       Date:  1995 Aug 7-21

6.  Varicella-zoster virus antibody avidity and IgG-subclass patterns in children with recurrent chickenpox.

Authors:  A K Junker; P Tilley
Journal:  J Med Virol       Date:  1994-06       Impact factor: 2.327

7.  Intracellular transport of newly synthesized varicella-zoster virus: final envelopment in the trans-Golgi network.

Authors:  A A Gershon; D L Sherman; Z Zhu; C A Gabel; R T Ambron; M D Gershon
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

8.  Infection of cells by varicella zoster virus: inhibition of viral entry by mannose 6-phosphate and heparin.

Authors:  Z Zhu; M D Gershon; R Ambron; C Gabel; A A Gershon
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-11       Impact factor: 11.205

9.  Famciclovir for the treatment of acute herpes zoster: effects on acute disease and postherpetic neuralgia. A randomized, double-blind, placebo-controlled trial. Collaborative Famciclovir Herpes Zoster Study Group.

Authors:  S Tyring; R A Barbarash; J E Nahlik; A Cunningham; J Marley; M Heng; T Jones; T Rea; R Boon; R Saltzman
Journal:  Ann Intern Med       Date:  1995-07-15       Impact factor: 25.391

10.  Tropism of varicella-zoster virus for human CD4+ and CD8+ T lymphocytes and epidermal cells in SCID-hu mice.

Authors:  J F Moffat; M D Stein; H Kaneshima; A M Arvin
Journal:  J Virol       Date:  1995-09       Impact factor: 5.103

View more
  61 in total

1.  Fifteen years of routine childhood varicella vaccination in the United States-strong decrease in the burden of varicella disease and no negative effects on the population level thus far.

Authors:  Andrea Streng; Johannes G Liese
Journal:  Transl Pediatr       Date:  2014-10

2.  Immune Correlates of Herpes Zoster in People Living with HIV on Effective Antiretroviral Therapy.

Authors:  Adriana Tovar Salazar; Ashley McKhann; Huichao Chen; Ronald J Bosch; Adriana Weinberg
Journal:  AIDS Res Hum Retroviruses       Date:  2019-07-16       Impact factor: 2.205

Review 3.  Evaluation of the economic burden of Herpes Zoster (HZ) infection.

Authors:  Donatella Panatto; Nicola Luigi Bragazzi; Emanuela Rizzitelli; Paolo Bonanni; Sara Boccalini; Giancarlo Icardi; Roberto Gasparini; Daniela Amicizia
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

4.  The herpes simplex virus 1 UL51 protein interacts with the UL7 protein and plays a role in its recruitment into the virion.

Authors:  Richard J Roller; Rachel Fetters
Journal:  J Virol       Date:  2014-12-31       Impact factor: 5.103

Review 5.  Varicella Virus Vaccination in the United States.

Authors:  Jana Shaw; Anne A Gershon
Journal:  Viral Immunol       Date:  2017-11-27       Impact factor: 2.257

Review 6.  Innate Sensing of DNA Virus Genomes.

Authors:  Zhe Ma; Guoxin Ni; Blossom Damania
Journal:  Annu Rev Virol       Date:  2018-09-29       Impact factor: 10.431

7.  Prevalence and Persistence of Varicella Antibodies in Previously Immunized Children and Youth With Perinatal HIV-1 Infection.

Authors:  Murli U Purswani; Brad Karalius; Tzy-Jyun Yao; D Scott Schmid; Sandra K Burchett; George K Siberry; Kunjal Patel; Russell B Van Dyke; Ram Yogev; Robert H Lurie; Ram Yogev; Margaret Ann Sanders; Kathleen Malee; Scott Hunter; William Shearer; Mary Paul; Norma Cooper; Lynnette Harris; Murli Purswani; Mahboobullah Baig; Anna Cintron; Ana Puga; Sandra Navarro; Patricia Garvie; James Blood; Sandra Burchett; Nancy Karthas; Betsy Kammerer; Andrew Wiznia; Marlene Burey; Molly Nozyce; Arry Dieudonne; Linda Bettica; Susan Adubato; Janet Chen; Maria Garcia Bulkley; Latreaca Ivey; Mitzie Grant; Katherine Knapp; Kim Allison; Megan Wilkins; Midnela Acevedo-Flores; Heida Rios; Vivian Olivera; Margarita Silio; Medea Jones; Patricia Sirois; Stephen Spector; Kim Norris; Sharon Nichols; Elizabeth McFarland; Alisa Katai; Jennifer Dunn; Suzanne Paul; Gwendolyn Scott; Patricia Bryan; Elizabeth Willen
Journal:  Clin Infect Dis       Date:  2015-09-18       Impact factor: 9.079

8.  The varicella-zoster virus portal protein is essential for cleavage and packaging of viral DNA.

Authors:  Melissa A Visalli; Brittany L House; Anca Selariu; Hua Zhu; Robert J Visalli
Journal:  J Virol       Date:  2014-05-07       Impact factor: 5.103

Review 9.  Reducing the burden of Herpes Zoster in Italy.

Authors:  Giovanni Gabutti; Elisabetta Franco; Paolo Bonanni; Michele Conversano; Antonio Ferro; Marzia Lazzari; Stefania Maggi; Alessandro Rossi; Silvestro Scotti; Francesco Vitale; Antonio Volpi; Donato Greco
Journal:  Hum Vaccin Immunother       Date:  2014-11-01       Impact factor: 3.452

Review 10.  Microbiology laboratory and the management of mother-child varicella-zoster virus infection.

Authors:  Massimo De Paschale; Pierangelo Clerici
Journal:  World J Virol       Date:  2016-08-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.